With the aim to dissect in vivo the role of the cancer cell-resident STING pathway within the tumor microenvironment, we took advantage from the retargeted HSV-1 based oncolytic virus R-LM113, which is able to selectively infect cells expressing the human HER2 receptor and, at the same time, is de-targeted from the natural cellular ligands [29]. This evidence concerns the gene STING1 and cancer.